Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Prof. Desire Collen, CEO

Dr. Patrik De Haes, COO

Tel: +32(0)16-34-61-94

Citigate Dewe Rogerson

Valerie Auffray / David Dible / Amber Bielecka

Tel: +44(0)207-638-95-71

valerie.auffray@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Genedata, a leading provider of ... and life science research, today announced AB Enzymes ... its bioinformatics platform for strain genome data management ... AB Enzymes, one of the world’s oldest and ... Genedata Selector accompanied by bioinformatics consulting services. Genedata ...
(Date:5/22/2013)... May 22, 2013 Mold remediation could take ... that there is a way to cut down the process' ... its latest post the details of a method how ... , Mold could be prevented, My Cleaning Products said. But ... stated that a mold remediation must then be promptly implemented ...
(Date:5/22/2013)... 2013 Envera announced today that Michael ... Mr. McErlean has an extensive background in cell production ... his career. , Mike Matheny, President and ... have Mike join our team”. “Mike’s background is perfectly ... fermentation and downstream processing equipment”, added Matheny. “Mike’s ...
(Date:5/22/2013)... 22, 2013  Moderna Therapeutics, the pioneering company developing ... enable the in vivo production of therapeutic ... will join Moderna in early July as its ... a proven leader in the design and implementation of ... discovery to translation, clinical operations and commercial preparedness. John ...
Breaking Biology Technology:AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Envera Appoints Michael McErlean Fermentation Manager 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3
... of Complex Arrhythmias Achieved Approval Considered ... Jan. 15 Stereotaxis, Inc. (Nasdaq:,STXS) announced today ... U.S. Food,and Drug Administration (FDA) has approved its ... ablation in the United States., "The long-awaited ...
... Detail Latest Cardiac Surgery Technology to be Held ... January 26th at 6:30 p.m. Eastern ... technology companies will host the first annual After Hours Event,on ... the yacht,"Princess Lady." The invitation-only event, immediately preceding the,largest meeting ...
... response to the,Federal Drug Administration,s announcement today that ... consumption, Smithfield Foods, Inc.,(NYSE: SFD ) reiterated ... produce meat products from cloned animals. The science ... leaders in our industry,we will continue to monitor ...
Cached Biology Technology:Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter 2Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter 3Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons 2Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons 3Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons 4
(Date:5/21/2013)... "place" is increasingly being considered in the management ... new resource that can help them recognize and ... places in their lives. , Place-Based Conservation: ... co-edited by the Pacific Northwest Research Station,s Linda ... to conservation. The book is published by Springer ...
(Date:5/21/2013)... become most deadly when they metastasize and spread tumors ... it becomes very difficult for doctors to locate and ... at the University of Missouri have found a way ... wherever they may be in the body. Michael Lewis, ... of Veterinary Medicine, says being able to target secondary ...
(Date:5/21/2013)... largest scientific society, invites news media coverage of ... 2013, in Indianapolis, Ind. It will take place ... hotels. , With more than 7,100 presentations on ... astronomy to zoology ― the meeting will offer ... of spot news and feature possibilities. The topics ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2
... with genetic risk of bowel cancer has found that ... of insurance implications. "This indicates that people have ... decision to have potentially life saving genetic testing," says ... Melbourne,s Key Centre for Women,s Health in Society. ...
... mayapple may soon offer an alternative to an Asian ... its anti-cancer properties. The near-extinct Asian plant, Podophyllyum ... etoposide, the active ingredient in a drug used for ... is a cousin of the common mayapple weed found ...
... This is the conclusion of a study which has analyzed the ... 14 years. The decrease in this activity and the fall in ... 10%) are the reasons why the "war", in the sense of ... Researchers from the Mediterranean Institute for Advanced Studies (IMEDEA-CSIC) ...
Cached Biology News:Fear of insurance rejection deters potentially life saving genetic tests for bowel cancer 2Anticancer compound found in American mayapple 2The war against wildlife comes to an end in Southern Europe 2
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
... pending) is a protein based inhibitor of ... the most common and troublesome RNases including ... SUPERaseIn can be used in any application ... is ideal for in vitro transcription and ...
... Printer) is a revolutionary new approach ... Macroarray Analysis, developed in conjunction with ... compliments established protocols in resolving proteins ... isoelectric point and apparent molecular weight). ...
Biology Products: